Abstract:OBJECTIVE To investigate the effects of human telomerase reverse transcriptase (hTERT) promoter and survivin promoter in tumor-specific gene therapy. METHODS hTERT promoter and survivin promoter were obtained by PCR using Jurkat genomic DNA. Recombinant adeno-associated virus (AAV) vectors containing exogenous TRAIL gene and hTERT promoter or survivin promoter were constructed and designated as rAAV-hTERT-TRAIL (h/TRAIL) or rAAV-survivin-TRAIL (s/TRAIL). rAAV particles were obtained after packing and purification and the virus titer was calculated by real-time PCR. Human hepatocellular carcinoma (HCC) cells of the lines SMMC-7721, BEL-7402, HepG2, and Hep3B, and primary human hepatocytes (PHHs) were transfected with h/TRAIL or s/TRAIL. Flow cytometry was used to detect the expression of the reporter gene enhanced green fluorescent protein (EGFP), so as to examine the activity of the two promoters. MTT method was used to detect the activity of the cells. Fifteen BalB/C mice underwent subcutaneous injection of SMMC-7721 cells so as to establish tumor models and then were randomly divided into 3 groups to undergo intra-tumor injection of h/TRAIL, s/TRAIL, or PBS. The growth of tumor was observed for 5 weeks, and then peripheral blood samples were collected to examine the serum AST and ALT levels. TUNEL was used to detect the apoptosis if the tumor cells. RESULTS All the SMMC-7721, BEL-7402, HepG2, and Hep3B cells driven by both h/TRAIL and s/TRAIL showed EGFP expression, however, no fluorescence could be seen in the PHHs transfected with h/TRAIL and s/ TRAIL. MTT method showed that 72 hours after the transfection of h/TRAIL and s/TRAIL the survival rates of the SMMC-7721, BEL-7402, and HepG2 cells all decreased, however, the survival rate of the Hep3B cells and PHHs did not changed significantly. The size of the subcutaneous tumor of the mice of the h/ TRAIL group was 625 mm3, significantly smaller than that of the PBS group (1500 mm3, P <0.05), however, the tumor size of the s/TRAIL group was 1117 mm3, not significantly different from that of the PBS group (P >0.05). The AST and ALT levels of all mice did not change significantly 5 weeks after the intratumor injection. CONCLUSION Tumor-specific promoters are promising candidates in targeted tumor gene therapy.

Analysis of Promoters and Expression-Targeted Gene Therapy Optimization Based on Doubling Time and Transfectability.

Promoter-Operating Targeted Expression of Gene Therapy in Cancer: Current Stage and Prospect

Unexpected Amplification of Synergistic Gene Expression to Boom Vascular Flow in Advantageous Dual-Gene Co-expression Plasmid Delivery Systems over Physically Mixed Strategy

[Effects of Human Telomerase Reverse Transcriptase Promoter and Survivin Promoter in Targeted Tumor Gene Therapy].

4:10 PM Abstract No. 50 Intratumoral Radiofrequency Hyperthermia-Enhanced Herpes Simplex Virus Thymidine Kinase (HSV-TK) Gene Therapy of Orthotopic Lung Cancer Through the Augmentation of Apoptosis and Heat Shock Protein (HSP70) Expression Pathway

Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters

Novel, Chimeric, Cancer-Specific, and Radiation-Inducible Gene Promoters for Suicide Gene Therapy of Cancer.

Development of Chimeric Gene Promoters Responsive to Hypoxia and Ionizing Radiation

[Transcriptional Targeting Gene Therapy of Double Suicide Gene Driven by Htert Promoter in Hepatic Carcinoma].

Expression of exogenous Muc1,Survivin and Nanog gene promoters in colon cancer stem cells

Levels Of Effectiveness Of Gene Therapies Targeting Survivin And Its Splice Variants In Human Breast Cancer Cells

Survioin promoter activity in tumor cell lines

653. the Controlled Transgene Expression in Oncolytic Adenoviral Vectors with Major Late Promoter for Therapy of Cancer

Molecular Engineering of a Two-Step Transcription Amplification (TSTA) System for Transgene Delivery in Prostate Cancer

From single to a dual-gene delivery nanosystem: coordinated expression matters for boosting the neovascularization in vivo.

Tumor-specific transcriptional targeting of suicide gene therapy

Incorporation of Prokaryotic Enhancer for Enhancement of Gene Expression Driven by Htert Promoter

Multiparameter Evaluation of in Vivo Gene Delivery Using Ultrasound-Guided, Microbubble-Enhanced Sonoporation.

Experimental Study on the Transcriptional Targeting Gene Therapy of Double Suicide Gene Driven by KDR Promotor in Lung Cancer

Hypoxia/radiation dual-sensitive promoters enhance the toxicity of HSVtk-mediated gene-directed enzyme prodrug therapy in Lung Cancer Cells

Therapeutic Efficacy Of An Htert Promoter-Driven Oncolytic Adenovirus That Expresses Apoptin In Gastric Carcinoma